|
Treatments
|
Concentrations
|
Mean ± s.e.m
|
|---|
|
control
|
0
|
248.3 ± 76.44
|
|
S. aureus (CFU ml-1)
|
106
|
328.8 ± 132.1
|
| |
107
|
170.0 ± 56.09
|
| |
108
|
2564 ± 1062
|
|
PAM 3 (ng ml-1)
|
3
|
405.3 ± 103.0
|
| |
30
|
2108 ± 531.5
|
| |
300
|
7994 ± 2178.0
|
|
FSL1 (ng ml-1)
|
10
|
370.6 ± 144.4
|
| |
100
|
509.0 ± 214.4
|
| |
1000
|
3792 ± 1379
|
|
MDPLys18 (10 nM)
|
10
|
218.1 ± 95.11
|
| |
100
|
444.1 ± 143.1
|
- Effect of Gram-positive bacteria and associated PAMPs on CXCL-8 release from human ASMCs over 48 h. ASMCs were treated either Gram-positive bacteria S. aureus, (106–108 CFU ml-1), Pam3CSK4 (3 – 300 ng ml-1), FSL-1, (10 – 1000 ng ml-1) or MDPLys18 (10 nM and 100 nM). The data represent the mean ± SEM of triplicate of three different donors.
